Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regen Biopharma Pref Shs RGBPP

Regen BioPharma Inc. is a biotechnology company. The Company is engaged on the immunology and immunotherapy space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. It is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. It is also developing products treating blood disorders using small molecules and... see more

Recent & Breaking News (OTCPK:RGBPP)

Regen BioPharma Inc. Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6

PR Newswire November 16, 2017

Regen BioPharma's Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs

PR Newswire November 8, 2017

Regen BioPharma, Inc. Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board (BAB)

PR Newswire October 30, 2017

Regen BioPharma, Inc. Begins Program to Determine the 3-Dimensional Crystal Structure of NR2F6

PR Newswire October 23, 2017

Regen BioPharma, Inc. Researchers Capitalize on Key Structure in Compounds that Activate Checkpoint NR2F6 for the Potential Treatment of Autoimmune Diseases

PR Newswire October 16, 2017

Regen BioPharma, Inc. Researchers Identify Key Structure in Compounds that Activate NR2F6

PR Newswire September 6, 2017

Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb $2.3 Billion Acquisition of IFM Therapeutics

PR Newswire August 9, 2017

Regen BioPharma, Inc. Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 Activators

PR Newswire July 25, 2017

Regen BioPharma, Inc. Researchers Discover New Dynamic Compound Which Modulates the NR2F6 Checkpoint

PR Newswire July 12, 2017

Regen BioPharma, Inc. Sees Additional Positive Results on its Medicinal Chemistry Optimization for Modulating NR2F6 Checkpoint for Treating Cancer and Autoimmune Diseases

PR Newswire May 16, 2017

Regen BioPharma, Inc. Sees Success in Its Pre-Clinical Small Molecule Optimization Program for NR2F6

PR Newswire April 12, 2017

Regen BioPharma, Inc. Provides Update on NR2F6 Small Molecule Optimization Program for Treating Cancer and Arthritis

PR Newswire March 23, 2017

Regen BioPharma, Inc. Licenses NR2F6 Technology for Cancer Treatment and Autoimmune Disorders to CheckPoint Immunology Inc.

PR Newswire March 2, 2017

Regen BioPharma Begins Optimization of NR2F6 Small Molecule Modulators

PR Newswire February 1, 2017

Regen BioPharma, Inc. Files Utility Patent Application on NR2F6-Silenced CAR-T Cell for Solid Tumors

PR Newswire December 15, 2016

Regen BioPharma, Inc. Discusses a Recent Important Discovery of NR2F6 in Human Cervical Cancer

PR Newswire December 7, 2016

Regen BioPharma's Chief Scientific Officer Harry Lander Provides Clarity on the Process of Small Molecule Development for Cancer and Autoimmune Diseases

PR Newswire November 16, 2016

Regen BioPharma, Inc. Discusses Next Steps in its NR2F6 Small Molecule Program

PR Newswire October 31, 2016

Pan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, Inc. for treatment of Bone Marrow Suppression Study

PR Newswire October 24, 2016

Entest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications

PR Newswire October 19, 2016